Posted by Michael Wonder on 15 Feb 2018
Alternative treatments for people with thyroid cancer to be offered routinely on the NHS, says NICE
15 February 2018 - The new guidance recommends three drugs, treating two types of thyroid cancer to be made routinely available in the NHS.
Cabozantib, also known as Cometriq, made by Ipsen and sorafenib, known as Nexavar made by Bayer have been recommended by NICE to come off the Cancer Drugs Fund and into routine use. Lenvatinib, or Lenvima made by Eisai has also been recommended for routine NHS use.
It is estimated by the companies that approximately 1,300 people could benefit from these treatments over the next five years.
